NCT06561243View on ClinicalTrials.gov

Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

Active, not recruitingOBSERVATIONAL
Enrollment

15,000

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

October 30, 2024

Conditions
Chronic B-cell MalignanciesBTK InhibitorsCardiovascular Diseases
Interventions
DRUG

BTK inhibitor (Ibrutinib or Acalabrutinib)

Adult patients with a chronic B-cell malignancy included in this study will be separate into 2 groups according to the BTK inhibitor (ibrutinib and acalabrutinib)

Trial Locations (1)

Unknown

Caen University Hospital, Department of Pharmacology, Caen

All Listed Sponsors
lead

University Hospital, Caen

OTHER